SCHEMBL19269

SCHEMBL19269

O=S(=O)(Cl)c1ccc(Cl)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.46
ALDH1A1 P00352 4/20 0.46
HTT P42858 3/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
TSHR P16473 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
PTGES2 Q9H7Z7 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4171406 0.87 MAPT (0.38) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL7132351 0.84 L3MBTL1 (0.46) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL4152423 0.80 KMT2A (0.46) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL11836425 0.78 F2 (0.44) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL185767 0.78 PTGES2 (0.53) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL301650 0.78 KMT2A (0.46) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL10050617 0.78 L3MBTL1 (0.47) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL1925734 0.78 KMT2A (0.44) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL11404135 0.78 KMT2A (0.44) KMT2AALDH1A1HTTGAAHPGD
SCHEMBL24254279 0.76 KMT2A (0.56) KMT2AALDH1A1HTTGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115304543-B Preparation method and product of aryl sulfonamide containing norbornenyl and application of aryl sulfonamide 南京林业大学 2024-08-20 CN claimed
CN-117050053-A Novel thiophene antitumor compound and preparation method and application thereof 北京中医药大学 2023-11-14 CN claimed
CN-115399179-A Application of polysaccharide-based cationic polymer in prevention and treatment of soil-borne diseases of agriculture and forestry 中国科学院化学研究所 2022-11-29 CN claimed
CN-115304543-A Preparation method of aryl sulfonamide containing norbornenyl, product and application thereof 南京林业大学 2022-11-08 CN claimed
WO-2013102936-A1 N-(3-((DIETHYLAMINO) METHYL)-4-HYDROXYPHENYL)-N-(QUINOLIN-4-YL) SULFONAMIDES FOR THE TREATMENT OF TUBERCULOSIS AND PROCESS OF PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-07-11 WO claimed
US-8440844-B2 Process for the preparation of β-amino alcohol COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-05-14 US claimed
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP claimed
US-20120330031-A1 Process for the Preparation of Beta-Amino Alcohol COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-12-27 US claimed
US-7838550-B2 Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols WYETH LLC (US) 2010-11-23 US claimed
US-7737303-B2 Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof WYETH LLC (US) 2010-06-15 US claimed
EP-1984347-A1 SELECTIVE N-SULFONYLATION OF 2-AMINO TRIFLUOROALKYL SUBSTITUTED ALCOHOLS Wyeth a Corporation of the State of Delaware (US) 2008-10-29 EP claimed
WO-2007127108-A1 PRODUCTION OF CHIRALLY PURE AMINO ALCOHOL INTERMEDIATES, DERIVATIVES THEREOF, AND USES THEREOF WYETH (US) 2007-11-08 WO claimed
US-20070249869-A1 Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof WYETH (US) 2007-10-25 US claimed
WO-2007098030-A1 SELECTIVE N-SULFONYLATION OF 2-AMINO TRIFLUOROALKYL SUBSTITUTED ALCOHOLS WYETH (US) 2007-08-30 WO claimed
US-20070197800-A1 Selective n-sulfonylation of 2-amino flouro-and trifluoroalkyl substituted alcohols WYETH (US) 2007-08-23 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-6800764-B2 PREPARING CHIRALLY PURE S-ENANTIOMERS OF ALPHA -AMINO ACIDS COMPRISING THE STEPS OF: A) PREPARING AN ORGANOMETALLIC REAGENT FROM AN ALKYL HALIDE OF THE FORMULA (R) 2CH(CH2)NCH2X; B) ADDING THE ORGANOMETALLIC REAGENT TO CARBON DIOXIDE TO FORM WYETH 2004-10-05 US claimed
EP-1461303-A2 PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE b-AMINO-ALCOHOLS Wyeth (US) 2004-09-29 EP claimed
US-20030144531-A1 Process for the synthesis of chirally pure beta-amino-alcohols WYETH (US) 2003-07-31 US claimed
WO-2003050063-A2 PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE β-AMINO-ALCOHOLS WYETH (US) 2003-06-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120330031-A1 Process for the Preparation of Beta-Amino Alcohol BACE1, BACE2, APP KMT2A 1681/4885ALDH1A1 24/4885HTT 1844/4885
US-20030144531-A1 Process for the synthesis of chirally pure beta-amino-alcohols ADH1C, ADH1A, ALDH7A1 KMT2A 1629/4885ALDH1A1 189/4885HTT 3711/4885
US-20070197800-A1 Selective n-sulfonylation of 2-amino flouro-and trifluoroalkyl substituted alcohols BRAF, AFF2, SELENOI KMT2A 262/4885ALDH1A1 1532/4885HTT 864/4885
US-20070249869-A1 Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof ADH1C, ADH1A, ACMSD KMT2A 77/4885ALDH1A1 51/4885HTT 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.